NZ741324A - Anti-cd47 antibodies and methods of use - Google Patents
Anti-cd47 antibodies and methods of useInfo
- Publication number
- NZ741324A NZ741324A NZ741324A NZ74132416A NZ741324A NZ 741324 A NZ741324 A NZ 741324A NZ 741324 A NZ741324 A NZ 741324A NZ 74132416 A NZ74132416 A NZ 74132416A NZ 741324 A NZ741324 A NZ 741324A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- methods
- expression
- manufacture
- disclosed
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221446P | 2015-09-21 | 2015-09-21 | |
| US201662371047P | 2016-08-04 | 2016-08-04 | |
| PCT/US2016/052878 WO2017053423A1 (en) | 2015-09-21 | 2016-09-21 | Anti-cd47 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ741324A true NZ741324A (en) | 2021-09-24 |
Family
ID=57043027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ741324A NZ741324A (en) | 2015-09-21 | 2016-09-21 | Anti-cd47 antibodies and methods of use |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9650441B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3353209B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018535692A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108290948B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016326423A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2999277A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2558131B (cg-RX-API-DMAC7.html) |
| HK (2) | HK1257309A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258257A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ741324A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017053423A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102489471B1 (ko) | 2014-12-30 | 2023-01-18 | 셀진 코포레이션 | 항-cd47 항체 및 그 용도 |
| AU2016326423A1 (en) | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| AU2017292752B2 (en) * | 2016-07-06 | 2023-07-27 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
| EP3487522A4 (en) | 2016-07-19 | 2020-04-01 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd47 combination therapy |
| BR112019008010A2 (pt) | 2016-10-20 | 2019-07-09 | I Mab | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| CA3042583A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| US20190309066A1 (en) * | 2017-03-22 | 2019-10-10 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| EP3601351A1 (en) * | 2017-03-27 | 2020-02-05 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
| IL269645B2 (en) | 2017-03-31 | 2025-05-01 | Genmab Holding B V | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| WO2018189382A1 (en) | 2017-04-14 | 2018-10-18 | Solstice Biologics, Ltd. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| WO2018236904A1 (en) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
| CN109096395B (zh) * | 2017-06-20 | 2022-06-24 | 华兰生物工程股份有限公司 | 阻断型cd47纳米抗体及其用途 |
| ES2976558T3 (es) | 2017-06-21 | 2024-08-05 | The Board Of Trustees Of The Leland Stanfordjunior Univ | Parámetros de dosificación para terapias de direccionamiento de CD47 en neoplasias hematológicas |
| PL3658141T3 (pl) * | 2017-07-24 | 2023-06-12 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| CN109422811A (zh) * | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CN108503708B (zh) * | 2017-09-01 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd47抗体及其用途 |
| EA039662B1 (ru) | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
| WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
| WO2019091473A1 (en) * | 2017-11-10 | 2019-05-16 | I-Mab Biopharma Co., Ltd. | Fusion proteins containing cd47 antibodies and cytokines |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| US11274123B2 (en) | 2018-01-12 | 2022-03-15 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling |
| US20210040224A1 (en) * | 2018-03-13 | 2021-02-11 | Trillium Therapeutics Inc. | Cd47 blockade therapy with cd38 antibody |
| CN110305212A (zh) * | 2018-03-27 | 2019-10-08 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| WO2019200357A1 (en) * | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
| CN110538321B (zh) * | 2018-05-29 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 一种cd47抗体药物组合物及其用途 |
| CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| WO2019241732A1 (en) * | 2018-06-15 | 2019-12-19 | Accurus Biosciences, Inc. | Blocking antibodies against cd47 and methods of use thereof |
| EP3817769A4 (en) * | 2018-07-05 | 2022-03-30 | Trican Biotechnology Co., Ltd | Human anti-cd47 antibodies and uses thereof |
| CA3110620C (en) * | 2018-08-31 | 2023-06-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-cd47 antibody and application thereof |
| WO2020072445A1 (en) * | 2018-10-01 | 2020-04-09 | Verastem, Inc. | Combination therapies |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3118312A1 (en) * | 2018-10-29 | 2020-05-07 | Tigatx, Inc. | Compositions and methods comprising iga antibody constructs |
| CA3118326A1 (en) | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
| KR20210088584A (ko) | 2018-11-08 | 2021-07-14 | 오리진 디스커버리 테크놀로지스 리미티드 | 소분자 cd-47 저해제와 다른 항암제의 조합물 |
| CN109224079B (zh) * | 2018-11-26 | 2020-08-04 | 中国药科大学 | Dna甲基转移酶抑制剂与抗cd47抗体联合用于制备抗肿瘤药物的医药用途 |
| US20220143180A1 (en) * | 2019-02-26 | 2022-05-12 | Innovent Biologics (Suzhou) Co., Ltd. | Formulation comprising anti-cd47 antibody, preparation method therefor and use thereof |
| TW202045550A (zh) | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
| CN114072172B (zh) * | 2019-04-18 | 2025-05-13 | Qlsf生物治疗药物公司 | 靶向人cd47的抗体 |
| EP3980747A1 (en) | 2019-06-07 | 2022-04-13 | ALX Oncology Inc. | Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays |
| CN112206320B (zh) * | 2019-07-12 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体冻干粉制剂及其制备工艺 |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| BR112022003868A2 (pt) * | 2019-09-03 | 2022-05-31 | Akeso Biopharma Inc | Anticorpo, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para preparar o anticorpo, conjugado de anticorpo, anticorpo multiespecífico, proteína de fusão, kit, linhagem de células de hibridoma, usos do anticorpo, composição farmacêutica, método in vivo ou in vitro |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| EP4048406A4 (en) * | 2019-10-23 | 2023-11-22 | Arch Oncology, Inc. | COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS |
| WO2021078219A1 (en) * | 2019-10-25 | 2021-04-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-cd47 antibodies and uses thereof |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| AU2020396548A1 (en) * | 2019-12-05 | 2022-07-14 | Vivasor, Inc. | Compositions and methods comprising an anti-CD47 antibody in combination with a tumor targeting antibody |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| PH12022551441A1 (en) | 2019-12-24 | 2023-11-20 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| JP2023509083A (ja) * | 2020-01-09 | 2023-03-06 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 腫瘍を予防又は治療するための薬物の調製における抗ｃｄ４７抗体と抗ｃｄ２０抗体の組み合わせの使用 |
| CR20220396A (es) | 2020-02-14 | 2022-11-14 | Jounce Therapeutics Inc | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos |
| US20230097658A1 (en) * | 2020-02-27 | 2023-03-30 | Fred Hutchinson Cancer Research Center | Tunable extended release hydrogels |
| EP4110830A4 (en) | 2020-02-28 | 2024-09-11 | Tallac Therapeutics, Inc. | TRANSGLUTAMINASE-MEDIATED CONJUGATION |
| CN111454359B (zh) * | 2020-03-23 | 2021-06-29 | 倍而达药业（苏州）有限公司 | Cd47抗体或其免疫活性片段及应用 |
| JP2023519346A (ja) | 2020-03-27 | 2023-05-10 | メンドゥス・ベスローテン・フェンノートシャップ | 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用 |
| AR121805A1 (es) * | 2020-04-10 | 2022-07-13 | Hutchison Medipharma Ltd | Anticuerpo anti-cd47 y usos del mismo |
| CN119930822B (zh) * | 2020-04-17 | 2025-11-21 | 鲁南制药集团股份有限公司 | 抗cd47单克隆抗体 |
| CA3172092A1 (en) * | 2020-04-23 | 2021-10-28 | David Cheresh | Compositions and methods for treating cancer |
| CA3181827A1 (en) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint |
| CA3182607A1 (en) | 2020-06-30 | 2022-01-06 | Erik Hans MANTING | Use of leukemia-derived cells in ovarian cancer vaccines |
| WO2022007947A1 (zh) * | 2020-07-10 | 2022-01-13 | 信达生物制药(苏州)有限公司 | 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途 |
| AU2021344635A1 (en) * | 2020-09-18 | 2023-04-27 | IGI Therapeutics SA | Cd47-cd38 bispecific antibodies |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| WO2022148383A1 (en) * | 2021-01-05 | 2022-07-14 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
| US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20240190993A1 (en) | 2021-04-14 | 2024-06-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method to improve the anti-tumoral activity of macrophages |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR102757524B1 (ko) * | 2021-06-30 | 2025-01-21 | (주)이노베이션바이오 | Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| ES2999273T3 (en) | 2022-03-17 | 2025-02-25 | Gilead Sciences Inc | Ikaros zinc finger family degraders and uses thereof |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| IL315879A (en) * | 2022-03-25 | 2024-11-01 | Wuxi Biologics Ireland Ltd | Anti-her2/anti-cd47 molecules and uses thereof |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024121311A1 (en) * | 2022-12-07 | 2024-06-13 | Ichnos Sciences SA | Cd47/cd38 bispecific antibodies and methods of use to treat leukemia |
| EP4637816A1 (en) * | 2022-12-22 | 2025-10-29 | The Medical College of Wisconsin, Inc. | Compositions that target cd138 and cd3 and methods of making and using the same |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024309A2 (en) * | 2023-07-21 | 2025-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of myeloid fcυ receptor depletion |
| TW202519517A (zh) | 2023-07-26 | 2025-05-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5057604A (en) | 1988-08-03 | 1991-10-15 | Washington University | Novel monoclonal antibodies |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5888751A (en) | 1997-07-15 | 1999-03-30 | Ludwig Institute For Cancer Research | Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells |
| CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| WO2000053634A1 (en) | 1999-03-10 | 2000-09-14 | Chugai Seiyaku Kabushiki Kaisha | Single-stranded fv inducing apoptosis |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| EP1455820A2 (en) | 2001-03-09 | 2004-09-15 | William Herman | Targeted ligands |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP4637749B2 (ja) | 2003-11-11 | 2011-02-23 | 中外製薬株式会社 | ヒト化抗ｃｄ４７抗体 |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| WO2007033221A2 (en) | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CN102596233A (zh) | 2009-05-15 | 2012-07-18 | 大学健康网络 | 用于以SIRPα-CD47的相互作用为靶标治疗血液癌症的组合物和方法 |
| PT2477648T (pt) | 2009-09-15 | 2022-10-27 | The Board Of Trustees Of The Univ Of The Leland Stanford Junior Univ | Terapia sinérgica anti-cd47 para cancros hematológicos |
| EP3181149A1 (en) | 2010-05-14 | 2017-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| CA2863834C (en) * | 2012-02-06 | 2024-09-10 | Inhibrx Biosciences, Inc. | Anti-CD47 antibodies and their methods of use |
| KR20150093770A (ko) | 2012-12-12 | 2015-08-18 | 베스쿨럭스 인코포레이티드 | 치료적 ｃｄ４７ 항체 |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP4137518A1 (en) | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| CN114917336A (zh) | 2013-03-15 | 2022-08-19 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| US10064925B2 (en) | 2013-04-29 | 2018-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-CD47 agents to enhance immunization |
| WO2014186761A2 (en) | 2013-05-17 | 2014-11-20 | The Board Of Trustes Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-cd47 agent |
| EP3046627B1 (en) | 2013-09-18 | 2019-10-23 | The Board of Trustees of the Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| AU2016326423A1 (en) * | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
-
2016
- 2016-09-21 AU AU2016326423A patent/AU2016326423A1/en not_active Abandoned
- 2016-09-21 CA CA2999277A patent/CA2999277A1/en not_active Abandoned
- 2016-09-21 CN CN201680060500.1A patent/CN108290948B/zh active Active
- 2016-09-21 US US15/271,861 patent/US9650441B2/en active Active
- 2016-09-21 HK HK18116460.7A patent/HK1257309A1/zh unknown
- 2016-09-21 GB GB1806466.7A patent/GB2558131B/en active Active
- 2016-09-21 NZ NZ741324A patent/NZ741324A/en unknown
- 2016-09-21 EP EP16774791.4A patent/EP3353209B1/en active Active
- 2016-09-21 HK HK18116461.6A patent/HK1257310A1/zh unknown
- 2016-09-21 JP JP2018534492A patent/JP2018535692A/ja not_active Ceased
- 2016-09-21 WO PCT/US2016/052878 patent/WO2017053423A1/en not_active Ceased
-
2017
- 2017-03-29 US US15/473,206 patent/US9803016B2/en active Active
- 2017-09-21 US US15/711,971 patent/US10442858B2/en not_active Expired - Fee Related
- 2017-09-21 US US15/712,010 patent/US10570201B2/en active Active
-
2018
- 2018-03-20 IL IL258257A patent/IL258257A/en unknown
-
2020
- 2020-01-16 US US16/744,733 patent/US20200291114A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9803016B2 (en) | 2017-10-31 |
| US9650441B2 (en) | 2017-05-16 |
| GB2558131B (en) | 2021-05-19 |
| EP3353209B1 (en) | 2022-03-16 |
| IL258257A (en) | 2018-05-31 |
| EP3353209A1 (en) | 2018-08-01 |
| US20200291114A1 (en) | 2020-09-17 |
| HK1257310A1 (zh) | 2019-10-18 |
| US10570201B2 (en) | 2020-02-25 |
| US20170081407A1 (en) | 2017-03-23 |
| GB201806466D0 (en) | 2018-06-06 |
| US20170204181A1 (en) | 2017-07-20 |
| CA2999277A1 (en) | 2017-03-30 |
| CN108290948B (zh) | 2021-10-29 |
| JP2018535692A (ja) | 2018-12-06 |
| US20180201677A1 (en) | 2018-07-19 |
| CN108290948A (zh) | 2018-07-17 |
| US10442858B2 (en) | 2019-10-15 |
| HK1257309A1 (zh) | 2019-10-18 |
| AU2016326423A1 (en) | 2018-04-26 |
| US20180105591A1 (en) | 2018-04-19 |
| WO2017053423A1 (en) | 2017-03-30 |
| GB2558131A (en) | 2018-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ741324A (en) | Anti-cd47 antibodies and methods of use | |
| CY1126115T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| PH12019502283A1 (en) | Anti-lag3 antibodies | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2020000960A (es) | Anticuerpos anti-tigit. | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| BR112017020054A2 (pt) | anticorpos para icos | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| JOP20200096A1 (ar) | جزيئات جسم مضاد لـ tim-3 واستخداماتها | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| PH12016500580B1 (en) | Conjugated antibodies against ly75 for the treatment of cancer | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| MX385775B (es) | Aparatos y métodos de selección de anticuerpo. | |
| GEP20217307B (en) | ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF | |
| MX2017011991A (es) | Terapia virica con una combinacion de anticuerpos. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| BR112016015693A2 (pt) | método para tratar um câncer de próstata e anticorpo | |
| MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. |